deriv
inhibit
viral
replic
cyclophilin
fkbp
b
r
c
recent
effect
drug
avail
block
coronaviru
cov
infect
human
anim
shown
csa
inhibit
coronaviru
replic
carbajolozoya
j
kalli
thiel
v
drosten
c
von
brunn
replic
human
coronavirus
sarscov
inhibit
drug
sarscoronavirushost
interactom
identif
cyclophilin
target
pancoronaviru
inhibitor
plo
pathog
demonstr
csd
alisporivir
well
novel
nonimmunosuppress
deriv
csa
strongli
inhibit
growth
human
coronaviru
low
micromolar
noncytotox
concentr
cell
cultur
show
qpcr
analysi
viru
replic
diminish
four
order
magnitud
background
level
knockdown
cellular
cyclophilin
cypappia
gene
cell
prevent
replic
suggest
cypa
requir
viru
replic
collect
result
uncov
cyclophilin
host
target
cov
infect
provid
new
strategi
urgent
need
therapeut
approach
coronavirus
caus
sever
diseas
respiratori
gastrointestin
tract
central
nervou
system
anim
perlman
netland
infect
human
known
sinc
mid
sixiti
associ
respiratori
tract
ie
common
coldlik
diseas
sarscov
sever
acut
respiratori
syndromecorona
viru
highli
aggress
human
agent
caus
lung
diseas
sar
often
fatal
outcom
drosten
et
al
viru
appear
epidem
cross
speci
barrier
like
bat
civet
cat
human
demonstr
potenti
coronavirus
caus
high
morbid
mortal
human
li
et
al
treatment
avail
epidem
could
eventu
control
highli
effect
tradit
public
health
measur
quarantin
case
isol
strain
discov
respect
van
der
hoek
et
al
woo
et
al
caus
sever
lower
respiratori
tract
infect
like
bronchiol
pneumonia
especi
young
children
van
der
hoek
new
human
cov
mer
middl
east
respiratori
syndrom
viru
previous
call
emc
emerg
middl
east
clinic
outcom
renal
failur
acut
pneumonia
similar
sarscov
even
higher
mortal
rate
de
groot
et
al
van
boheemen
et
al
zaki
et
al
human
coronavirus
caus
approxim
upper
lower
respiratori
tract
infect
account
signific
hospit
children
year
age
elderli
immunocompromis
individu
accord
number
intern
studi
acut
respiratori
diseas
caus
review
see
abdulrasool
field
number
probabl
underestim
regard
gener
popul
sinc
routin
diagnost
screen
respiratori
virus
test
hcov
frequent
includ
import
aspect
infect
coinfect
human
coronavirus
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
human
metapneumoviru
abdulrasool
field
children
associ
acut
respiratori
tract
ill
pneumonia
croup
lead
mani
case
hospit
recent
epidemiolog
studi
hospit
children
hcovposit
dijkman
et
al
infect
frequenc
children
mild
symptom
hospit
children
occur
order
largescal
survey
diagnost
respiratori
sampl
collect
edinburgh
uk
posit
least
one
coronaviru
account
viru
detect
gaunt
et
al
coronavirus
detect
present
sampl
test
posit
respiratori
virus
eg
rsv
inhibitor
coronaviru
enzym
review
tong
b
compound
inhibit
vitro
replic
describ
kono
et
al
milewska
et
al
pyrc
et
al
te
velthui
et
al
vincent
et
al
instens
studi
antivir
compound
direct
viral
proteas
present
mammalian
host
chaudhuri
et
al
chuck
et
al
chuck
et
al
yang
et
al
zhu
et
al
howev
clinic
licens
antivir
coronaviru
infect
absent
coronavirus
repres
group
largest
singlestrand
rna
virus
plu
strand
orient
gener
rna
virus
replic
low
fidel
thu
prone
rapid
evolutionari
chang
although
coronavirus
encod
proofread
exoribonucleas
exon
increas
replic
robust
larg
genom
mutat
within
domain
increas
mutat
rate
significantli
smith
denison
viru
replic
depend
varieti
host
factor
de
haan
rottier
vogel
et
al
wang
li
repres
potenti
antivir
target
might
prefer
target
viral
protein
develop
resist
much
less
like
recent
studi
perform
genomewid
sarscov
yeasttwohybrid
interact
screen
human
cdna
librari
identifi
human
immunophilin
includ
cyclophilin
cyp
protein
fkbp
interact
partner
cov
nonstructur
protein
pfefferl
et
al
pronounc
featur
mammalian
cyclophilin
abil
bind
immunosuppress
drug
cyclosporin
csa
show
drug
act
replic
inhibitor
number
human
sarscov
anim
coronavirus
felin
cov
serotyp
ii
porcin
transmiss
gastroenter
viru
tgev
avian
infecti
bronchiti
viru
ibv
suggest
host
cyclophilin
target
pancoronaviru
inhibit
pfefferl
et
al
inhibit
sarscov
addit
mous
hepat
viru
mhv
subsequ
also
confirm
de
wild
et
al
inhibit
felin
cov
replic
also
found
tanaka
et
al
similarli
show
inhibit
replic
sarscov
depend
carbajolozoya
et
al
cyclophilin
fkbp
repres
larg
independ
famili
peptidylprolyl
cistran
isomeras
ppias
ec
number
thu
exert
import
function
fold
matur
traffick
protein
within
eukaryot
cell
blackburn
walkinshaw
davi
et
al
csa
act
tightbind
revers
competit
inhibitor
activ
site
enzym
fischer
et
al
physic
interact
cyclophilin
viral
protein
thu
replic
sensit
csa
shown
sever
virus
eg
capsid
protein
human
immunodefici
viru
strebel
et
al
ylinen
et
al
human
papilloma
viru
hpv
type
bienkowskahaba
et
al
n
protein
vesicular
stomat
viru
bose
et
al
hepat
c
viru
hcv
fernand
et
al
fischer
et
al
protein
mosquitoborn
japanes
enceph
viru
kambara
et
al
protein
west
nile
viru
qing
et
al
protein
influenza
viru
liu
et
al
promin
cyclophilin
thought
involv
cypa
cypb
ppiaseindepend
activ
csa
exert
gainoffunct
result
binari
complex
form
bind
drug
cyp
fkbp
respect
base
inhibit
protein
phosphatas
activ
calcineurin
complex
block
cellular
calcineurin
nfat
pathway
therebi
interf
tcell
activ
product
chemic
chang
deriv
cover
specif
sidechain
modif
socal
nonimmunosuppress
cyclosporin
analogu
discrimin
altern
signal
pathway
either
base
ppiaseor
caninhibit
function
identifi
interact
sarscov
protein
cyp
fkbp
sensit
cov
replic
drug
csa
suggest
csa
potenti
pancov
inhibitor
pfefferl
et
al
demonstr
use
alisporivir
seri
newli
synthes
csa
deriv
inhibit
replic
independ
immunosuppress
charact
compound
show
cypa
cypb
requir
viru
replic
mous
antibodi
recogn
nprotein
obtain
ingenasa
spain
sastr
et
al
antilamin
purchas
biomol
hamburg
germani
goatantilamin
b
rabbit
anticypa
rabbit
anticypb
obtain
santa
cruz
biotechnolog
enzo
life
scienc
abcam
respect
secondari
antibodi
receiv
dianova
goat
antirabbitighors
radish
peroxidas
hrp
rabbitantigoatighrp
sigma
antimouseighrp
compound
synthes
previous
describ
prell
et
al
synthesi
describ
elsewher
alisporivir
gener
provid
novarti
switzerland
csa
csd
obtain
sigmaaldrich
santa
cruz
germani
enzo
life
scienc
germani
respect
tabl
shrna
sequenc
use
lentiviralbas
gene
knockdown
sequenc
primer
use
quantif
gene
knockdown
b
test
perform
describ
briefli
jurkat
cell
transfect
nfat
report
gene
plasmid
incub
inhibitor
dmso
control
min
ca
mobil
initi
phorbol
tumor
necrosi
cultur
addit
h
harvest
determin
luciferas
activ
cell
lysat
nfat
activ
express
mean
sd
triplic
three
independ
experi
hela
cell
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fc
penicillinstreptomycin
plasmid
transfect
hela
cell
use
lipofectamin
ltx
plu
reagent
life
technolog
cell
confluent
subsequ
drug
ad
medium
final
concentr
nm
h
later
ionomycin
ad
final
concentr
induc
transloc
pictur
taken
use
fluoresc
microscop
leica
b
min
ionomycin
induct
cell
infect
moi
h
remov
viru
inoculum
two
pb
wash
fresh
medium
supplement
increas
inhibitor
concentr
ad
h
rna
extract
l
cultur
supernat
use
high
pure
viral
nucleic
acid
kit
roch
elut
l
quantif
done
realtim
pcr
sensifast
probe
hirox
onestep
kit
biolin
gmbh
germani
allow
revers
transcript
cdna
synthesi
pcr
amplif
singl
step
sampl
analyz
abi
prism
cycler
sequenc
detect
system
standard
curv
produc
use
serial
dilut
viral
rna
viru
stock
known
viru
titer
pcr
primer
herzog
et
al
use
genom
posit
nt
agacgtcgttgtagatccctaa
genom
posit
nt
probe
genom
posit
nt
determin
nprotein
express
presenc
inhibitor
cell
infect
viru
moi
one
hour
sixwel
plate
viru
wash
pb
inhibitor
ad
medium
respect
concentr
h
cell
harvest
lyse
mm
trishcl
ph
mm
nacl
mm
dtt
proteas
inhibitor
cocktail
hoffmann
la
roch
l
lysi
buffer
protein
separ
sdspage
electroblot
onto
nitrocellulos
membran
latter
block
milk
powder
tbst
mm
nacl
mm
trishcl
ph
tween
buffer
incub
primari
antibodi
usual
carri
c
overnight
secondari
antibodi
incub
perform
room
temperatur
h
incub
step
membran
wash
three
time
tbst
min
hrp
develop
immobilon
western
blot
hrp
chemiluminisc
substrat
milipor
membran
expos
xray
film
agfa
cell
cultur
dulbecco
modifi
eagl
medium
dmem
contain
fc
penicillinstreptomycin
cyclophilin
knockdown
cell
line
gener
use
shrna
express
vector
sirion
gmbh
martinsri
germani
recent
describ
carbajolozoya
et
al
briefli
cell
transduc
moi
missiontm
lentivir
nontarget
control
gene
ppia
target
set
shvrsnm
ppib
target
set
shvrsnm
sequenc
use
gene
knockdown
list
tabl
stabli
shrnaexpress
cell
gener
week
bulkselect
gml
puromycincontain
medium
dmem
fc
mm
lglutamin
mm
napyruv
first
csa
analogu
isol
trichoderma
polysporum
traber
et
al
csd
describ
weak
immunosuppress
lymphocyt
prolifer
assay
csa
activ
sadeg
et
al
b
csd
valin
locat
posit
instead
acid
two
promin
csa
deriv
contain
methylisoleucin
posit
instead
methylleucin
alisporivir
contain
methylalanin
posit
instead
sarcosin
nethyl
valin
posit
instead
nmethyl
leucin
intens
test
clinic
trial
antihcv
drug
fischer
et
al
gallay
lin
lin
gallay
membreno
et
al
vermehren
sarrazin
set
csa
analogu
develop
finetun
derivat
mebmt
residu
csa
deriv
differ
properti
regard
inhibit
drugcypfkbp
complex
phosphatas
nfat
activ
fig
tabl
synthesi
drug
deriv
compound
previous
describ
csa
deriv
synthes
recent
publish
chemic
synthesi
nonimmunosuppress
analogu
start
parent
drug
publish
elsewher
ppias
inhibitor
biochem
character
determin
inhibitori
potenc
standard
ppias
assay
inhibit
phosphatas
influenc
cellbas
nfat
report
gene
activ
nfat
transloc
drug
tabl
perform
use
publish
procedur
pfefferl
et
al
prell
et
al
ic
valu
ppias
inhibit
similar
csa
compound
nm
show
higher
ic
valu
indic
lower
bind
affin
inhibit
still
found
low
nanomolar
rang
cna
activ
could
inhibit
binari
ppiasedrug
complex
contrast
cna
activ
weakli
inhibit
high
concentr
drugcypa
complex
indic
ic
valu
rang
compound
ic
ic
ic
addit
deriv
also
demonstr
low
abil
ic
respect
compar
csa
ic
nm
reduc
nfatdriven
report
gene
express
luciferasecoupl
nfat
report
gene
assay
indic
greatli
diminish
immunosuppress
activ
cellular
assay
although
peptid
show
higher
cna
properti
csa
compound
compound
analogu
respect
inhibit
ppia
proteasecoupl
ppias
assay
inhibit
nfat
nfatgfp
nuclear
transloc
method
describ
prell
et
al
last
column
repres
inhibitori
valu
peptid
infect
cell
inhibit
vitro
nfat
inhibit
remark
indic
gain
effect
vivo
nfat
inhibitori
activ
still
repres
lower
influenc
csa
deriv
nfatregul
signal
pathway
compar
csa
drug
deriv
character
nfatgfp
nuclear
transloc
assay
hela
cell
transfect
plasmid
encod
nfatgfp
fusion
construct
control
cmv
promot
fig
upon
ca
mobil
ionomycin
cellular
phosphatas
dehosphoryl
nfat
transcript
factor
subsequ
transloc
nucleu
cell
synchron
nfatgfp
transloc
expect
occur
simultan
explain
minor
transfer
effici
cell
cypbind
immunosuppress
csa
csd
fkbpbind
induc
bind
protein
complex
thu
inactiv
phosphatas
activ
result
nfat
transfer
nucleu
complex
modifi
drug
type
ppias
ie
cypmodifi
csa
fkbpmodifi
deriv
complex
greatli
reduc
potenc
inhibit
thu
might
allow
transloc
nfat
nucleu
transcript
regul
immun
gene
consequ
alv
whole
seri
newli
synthes
drug
deriv
clearli
allow
nfatgfp
transloc
nucleu
thu
consid
nonimmunosuppress
assay
condit
tabl
conclus
three
differ
assay
synthet
drug
deriv
prove
inert
nearli
inert
suppress
cellular
immun
respons
almost
unchang
bind
inhibitori
potenc
ppias
activ
respect
drug
receptor
examin
inhibitori
effect
describ
nonimmunosuppress
csa
deriv
replic
cell
infect
describ
carbajolozoya
et
al
fig
show
effect
csa
seven
nonimmunosuppress
deriv
alv
descend
replic
cell
left
panel
repres
percentag
reduct
viru
replic
left
yax
cell
viabil
right
yax
right
panel
indic
respect
titer
reduct
figur
show
two
independ
set
experi
fig
b
carri
differ
time
use
differ
batch
csa
perform
individu
viru
inhibit
experi
csa
alway
includ
intern
control
minor
variat
explain
use
differ
compound
batch
fig
summar
result
obtain
peptid
csa
alv
fig
delin
result
peptid
csd
combin
two
peptid
individu
graph
chosen
arbitrarili
deriv
group
togeth
belong
compound
famili
inhibit
curv
conclud
peptid
test
ie
csa
csd
well
alv
new
deriv
clearli
inhibit
replic
cell
low
micromolar
concentr
level
ec
inhibitori
score
tabl
resid
rang
show
lowest
highest
concentr
respect
act
similarli
also
deriv
behav
similar
ancestor
molecul
clear
correl
inhibitori
effect
vitro
inhibit
cypa
cna
nfat
activ
studi
effect
csa
alv
substanc
viral
protein
express
cell
incub
concentr
respect
inhibitor
h
western
blot
analysi
cell
perform
util
antinprotein
antibodi
fig
clearli
show
signific
decreas
nprotein
detect
respect
inhibitor
suggest
drug
inhibit
import
step
viral
replic
cycl
order
examin
whether
cellular
cypa
cypb
encod
ppia
ppib
gene
respect
requir
replic
cyclophilin
knockdown
cell
line
establish
use
lentivir
shrna
express
vector
recent
describ
carbajolozoya
et
al
rather
high
puromycin
concentr
gml
need
select
cell
effici
deplet
inhibitori
drug
molecul
enhanc
express
multi
drug
resist
protein
gene
takara
et
al
character
cyp
cypb
knockdown
qualiti
mrna
express
quantifi
initi
bulkselect
knockdown
control
cell
realtim
rtpcr
revers
transcript
g
total
rna
use
amplif
product
detect
sybr
amplicon
integr
verifi
melt
point
analysi
human
topoisomeras
gene
serv
refer
gene
nontarget
control
ppia
ppib
determin
specif
knockdown
mrna
express
level
ppia
ppib
determin
realtim
rtpcr
primer
list
tabl
case
ppia
knockdown
puromycin
bulkselect
cell
incomplet
determin
western
blot
qpcr
analysi
viru
growth
detect
qpcr
shown
surpris
result
cypa
compris
total
cytosol
protein
eukaryot
tissu
hard
et
al
therefor
reason
cell
appropri
test
effect
cypa
viru
replic
necessari
search
better
qualiti
knockdown
clone
individu
cell
clone
select
bulk
kd
cell
limit
dilut
presenc
puromycin
check
knockdown
qualiti
individu
clone
expand
test
express
western
blot
qpcr
fig
fig
show
western
blot
analys
ppia
kd
clone
polyclon
rabbit
anticypa
use
infect
experi
cypb
kd
demonstr
fig
use
polyclon
rabbit
anticypb
antibodi
control
housekeep
gene
lamin
b
probe
polyclon
goat
antilamin
b
antibodi
lamin
b
level
show
differ
control
knockdown
cell
cypa
bare
detect
cypb
complet
reduc
qpcr
comparison
nontarget
control
cypa
cypb
knockdown
cell
line
determin
respect
fig
examin
viru
propag
knockdown
cell
line
control
kd
kd
cell
infect
serial
dilut
plaqu
titrat
clearli
show
compar
viru
titer
fig
control
cell
line
viru
grow
kd
cell
indic
depend
viru
replic
cypa
similar
result
obtain
qpcr
shown
common
mani
case
success
antivir
therapeut
approach
adher
use
drug
inhibit
viral
replic
directli
act
viral
compon
import
viral
life
cycl
like
revers
transcriptas
proteas
integras
etc
drawback
drug
high
mutat
suscept
viral
genom
due
poor
proofread
activ
viral
replic
enzym
especi
rna
virus
difficulti
might
circumv
new
promis
therapeut
drug
target
host
factor
involv
viral
entri
replic
assembl
releas
gener
cellular
function
protein
translat
fold
well
character
exampl
inhibit
hepat
c
viru
infect
cell
cultur
model
human
hosttarget
agent
zeisel
et
al
cyclophilin
class
mostli
intracellular
enzym
requir
correct
fold
function
variou
cellular
also
viral
protein
von
hahn
et
al
cypa
shown
bind
sever
hcv
protein
essenti
replic
sever
virus
inhibit
csa
nonimmunosuppress
deriv
thereof
baugh
gallay
daeleman
et
al
fassati
frausto
et
al
gallay
membreno
et
al
hcv
patient
safeti
efficaci
shown
three
cyp
inhibitor
alv
novarti
scynexi
phase
phase
ii
trial
alv
firstinclass
advanc
cyclophilin
inhibitor
clinic
proofofconcept
includ
phase
iii
random
clinic
trial
flisiak
et
al
gallay
lin
membreno
et
al
unbias
yeasttwohybrid
screen
found
protein
sarscov
pfefferl
et
al
et
al
cov
unpublish
bind
cyclophilin
includ
cypa
csa
inhibit
coronavirus
includ
human
sarscov
anim
cov
fcov
two
serotyp
ibv
tgev
show
inhibitori
action
three
human
cov
main
goal
studi
test
compar
inhibitori
effect
chemic
difficulttosynthes
cyclosporin
alv
set
drug
deriv
result
chemic
welltract
side
chain
posit
csa
addit
deriv
provid
first
indic
feasibl
expand
concept
antivir
nonimmunosuppress
cypa
inhibitor
field
fkbp
inhibitor
data
inhibit
replic
compar
immunosuppress
immunophilin
binder
csa
csd
deriv
inhibit
ppias
activ
respect
bind
protein
thu
prevent
catalyt
function
assist
client
protein
fold
correctli
compar
alreadi
known
nonimmunosuppress
drug
new
compound
easili
access
chemic
synthesi
also
show
favor
ratio
ppias
inhibit
cellular
toxic
compound
test
nfatgfp
nuclear
transloc
assay
fig
upon
mobil
ca
ionomycin
nfatgfp
remain
cytoplasm
presenc
csa
csd
indic
cypacsa
cypacsd
complex
inactiv
phosphatas
thu
prevent
nfat
dephosphoryl
nuclear
transloc
constitut
basi
immunosuppress
csd
clear
exert
rather
strong
immunosuppress
activ
oppos
earlier
report
ascrib
csa
activ
molecul
sadeg
et
al
presenc
alv
newli
synthes
drug
deriv
nfat
migrat
nucleu
within
minut
confirm
nonimmunosuppress
activ
new
set
drug
also
character
vitro
respect
inhibit
cypa
proteasecoupl
ppias
assay
cna
nfat
assay
cell
permeabl
potenc
ppias
inhibit
compar
csa
case
compound
increas
sixfold
ic
valu
cna
inhibit
achiev
csa
wherea
three
new
compound
higher
concentr
need
viru
inhibit
experi
fig
tabl
clearli
show
highli
effect
inhibit
alv
ec
ec
close
resembl
pattern
csa
ec
csd
ec
ec
valu
csa
deriv
rang
ec
valu
deriv
respect
taken
togeth
deriv
inhibit
viru
replic
low
micromolar
rang
similar
previou
report
inhibit
variou
human
anim
cov
csa
pfefferl
et
al
interestingli
inhibit
hcv
csa
alv
commonli
observ
nanomolar
concentr
alv
effect
compound
explan
specul
case
hcv
interact
viral
protein
cyclophilin
sensit
inhibitor
micromolar
rang
cov
inhibit
nice
confirm
anoth
group
de
wild
et
al
protein
play
crucial
role
viral
life
cycl
analyz
repres
viral
protein
express
presenc
increas
concentr
csa
alv
substanc
protein
decreas
detect
concentr
thu
clear
inhibitori
effect
differ
peptid
n
protein
express
viru
replic
whether
inhibit
result
lack
cyclophilin
interact
anoth
viral
protein
decid
current
stage
n
protein
sarscov
column
right
yax
indic
percentag
cell
viabil
xax
indic
increas
inhibitor
concentr
viru
replic
determin
closedopen
squar
closedopen
circl
repres
reduct
genom
equival
cell
viabil
indic
inhibitor
concentr
xax
respect
graph
plot
use
prism
graphpad
softwar
inc
nonlinear
regress
variabl
slope
algorithm
curv
fit
respect
inhibitor
calcul
report
bind
cypa
luo
et
al
cypa
incorpor
sarscov
particl
neuman
et
al
inhibitor
might
also
act
directli
cypanprotein
complex
also
exist
also
rule
viral
protein
requir
cypa
function
import
question
whether
cypa
crucial
cyclophilin
requir
cov
replic
hcv
discrep
necess
cypa
cypb
viru
growth
recent
studi
demonstr
cypa
key
host
factor
hcv
replic
baugh
gallay
kaul
et
al
order
address
role
two
member
cyp
famili
replic
develop
cell
line
individu
knockdown
cypa
cypb
lentivir
basi
fig
character
protein
fig
rna
fig
level
indic
effici
kd
two
cyp
plaqu
titrat
experi
perform
nontarget
cypb
viru
grew
compar
titer
fig
contrast
cypa
cell
support
viru
growth
indic
depend
function
cypa
regard
cyp
requir
cov
replic
contradictori
result
report
de
wild
et
al
cov
data
csa
inhibit
et
al
basic
confirm
report
claim
neither
cypa
cypb
requir
replic
sarscov
mous
hepat
viru
mhv
basi
sirna
ppia
ppib
knockdown
experi
howev
sirna
knockdown
rather
incomplet
term
residu
cypa
cypb
protein
level
leav
enough
ppias
activ
infect
cell
support
viral
replic
least
clearli
demonstr
lentivir
produc
knockdown
cell
cypa
cypb
requir
molecul
interestingli
show
similarli
poor
knockdown
ppia
author
claim
followup
studi
arterivirus
ppia
requir
cyclophilin
nidoviru
replic
de
wild
et
al
coronavirida
arterivirida
famili
within
order
nidoviral
positivestrand
similar
genom
organ
genom
length
kb
kb
respect
share
number
enzymat
function
sinc
famili
sensit
csa
involv
cyclophilin
nidoviru
replic
gener
principl
reason
infect
studi
kd
cell
conclud
abund
cypa
viral
host
prerequisit
cov
replic
interact
sarscov
mammalian
proteinbind
assay
sever
cyclophilin
isoform
suggest
potenti
involv
addit
cyclophilin
infect
process
examin
systemat
whether
cypa
cyclophilin
bind
viral
protein
furthermor
knowledg
regulatori
role
catalyt
activ
ppias
subfamili
cyclophilin
protein
shown
critic
viral
replic
process
requir
identif
protein
substrat
coronavir
background
four
nonsarsrel
hcov
major
caus
rel
mild
respiratori
tract
infect
immunocompet
host
howev
clinic
manifest
like
bronchiol
pneumonia
sever
especi
young
children
elderli
immunocompromis
patient
van
der
hoek
infect
occur
earli
childhood
detect
anti
igg
antibodi
gener
human
popul
demonstr
high
preval
zhou
et
al
furthermor
zoonot
transmiss
potenti
huynh
et
al
highli
aggress
sarscov
merscov
gallagh
perlman
demand
develop
effect
drug
prevent
allevi
viru
growth
pathogen
mark
inhibit
replic
nonimmunosuppress
deriv
csa
highlight
function
relev
host
cell
cyclophilin
fkbp
antivir
target
fig
character
cypa
cypb
knockdown
cell
growth
analysi
cypa
cypb
express
determin
western
blot
use
anticypa
anticypb
antibodi
qpcr
b
lamin
b
detect
antilamin
b
antibodi
load
control
use
qpcr
standard
cyclophilin
express
growth
wt
shctr
nontarget
cell
cypa
cypa
kd
cypb
cypb
kd
knockdown
mutant
analyz
plaqu
titrat
assay
viru
titer
depict
c
